. 3

.

M., May J., Gaither T. A., Ellman L. In vitro studies of complement function in sera of C4-deficient guinea pigs, J. Exp. Med., 134, 176190 (1971).

37. Root R. K., Ellman L., Frank M. M. Bactericidal and opsonic properties of C4-deficient guinea pig serum, J. Immunol., 109, 477486 (1972).

38. Gotze O., Milller-Eberhard ff. J. The C3 activator system: An alternate pathway of complement activation, J. Exp. Med., 134, 90S108S (1971).

39. Lesavre P. H., Muller-Eberhard ff. J. Mechanism of action of Factor D of the alternative complement pathway, J. Exp. Med., 148, 14981509 (1978).

40. Fearon D. ., Austen K. F., Ruddy S. Properdin Factor D: Characterization of its active site and isolation of the precursor form, J. Exp. Med., 139, 355366 (1974).

41. Davis A. E., Zalut C, Rosen F. S., Alper C. A. Human Factor D of the alternate complement pathway. Physicochemical characteristics and N-terminal amino acid sequence, Biochemistry, 18, 50825087 (1979).

42. ffugli T. E., Muller-Eberhard ff. J. Anaphylotoxins: and C5a, Adv. Immunol., 26, 153 (1978). . . , . . , . .

43. Raum D., Glass D., Carpenter ., A Iper D. A ., Shur P. H. The chromosomal order of genes controlling the major histocompatibility complex, properdin Factor and deficiency of the second component of complement, J. Clin. Invest., 58, 12401248 (1976).

44. Minta J. O., Lepow I. H. Studies on the subunit structure of human properdin, Immunochemistry, 11, 361368 (1974).

45. Medicus R. G., Esser A. F., Fernandez H. N., Muller-Eberhard H. J. Native and activated properdin: Interconvertibility and identity of amino acid carboxy terminal sequences, J. Immunol., 124, 602606 (1980).

46. Konno ., Hirai H., Tomura N. Binding of activated properdin to untreated erythrocytes, Immunology, 34, 207215 (1978).

47. Whaley K., Ruddy S. Modulation of the alternative pathway by B1H globulin, J. Exp. Med., 144, 11471163 (1976).

48. Gaither T. A., Hammer . H., Frank M. M. Studies of the molecular mechanisms of C3b inactivation and a simplified assay of (H and the C3b inactivator, J. Immunol., 123, 1195 (1979).

49. Harrison R. A., Lachmann P. J. The phsyiological breakdown of the third component of complement, Mol. Immunol., 17, 920 (1980).

50. Hsiung L., Barclary A. N., Gagnon J., Brandon M. R., Porter R. R. The C3b inactivator is a serine proteinase, Mol. Immunol., 19, 1376 (Abstract) (1982).

51. Davis A. E. Human C3b inactivator: Sequence homology with serine proteases, Mol. Immunol., 19, 1367 (Abstract) (1982).

52. Tack B. F., Morris S. C, Prahl J. W. Third component of human complement: Structural analysis of the polypeptide chains of C3 and . Biochemistry, 18, 14971505 (1979).

53. Isenman D. E., Cooper N. R. The structure and function of the third component of complement. I. The nature and extent of conformational changes accompanying C3 activation, Mol. Immunol., 18, 331339 (1981).

54. Tack B. F., Harrison R. A., Janatova J., Thomas M. L., Prahl J. W. Evidence for presence of an internal thioester bond in third component of human complement, Proc. Natl. Acad. Sci. USA, 77, 57645768 (1980).

55. Janatova J., Lorenz P. E., Schecter A. N., Prahl J. W., Tack B. F. Third component of human complement: Appearance of a sulfhydryl group after chemical or enzymatic inactivation, Biochemistry, 19, 44714478 (1980).

56. Thomas M. L., Janatova J., Gray W. R., Tack B. F. Third component of human complement: Localization of the internal thioester bond, Proc. Natl. Acad. Sci. USA, 79, 1054 1058 (1982).

57. Law S. K., Levine R. P. Interaction between the third complement protein and cell surface macromolecules, Proc. Natl. Acad. Sci. USA, 74, 27012705 (1977).

58. Mann J., O'Brien R., Hostetter M. K., Alper C. A., Rosen F. S., Babior . M. The third component of complement: Covalent attachment of radioactive sugar to the labile binding site of C3 via alternative pathway, J. Immunol., 126, 23702372 (1981).

59. Janatova J., Tack B. F., Prahl J. W. Third component of human complement: Requirements for its function, Biochemistry, 19, 44794485 (1980).

60. Law S. K., Minich T. M., Levine R. P. The binding reaction between C3b and small molecules in solution, Mol. Immunol., 19, 1383 (Abstract) (1982).

61. Pangburn M. K., Schreiber R. D., Muller-Eberhard H. J. Human complement inactivator: Isolation, characterization, and demonstration of an absolute requirement for the serum protein fJlH for cleavage of and C4b in solution, J. Exp. Med., 146, 257270 (1977).

62. Lachmann P. J., Oldsoyd R. G., Milstein C, Wright . W. Three rat monoclonal antibodies to human C3, Immunology, 41, 503515 (1980).

63. Lachmann P. J., Pangburn M. K., Oldroyd R. G. Breackdown of C3 after complement activation: Identification of a new fragment C3g, using monoclonal antibodies, J. Exp. Med., 156, 205-216 (1982).

64. Medicus R. G., Arnaut M. A. Release of C3c from bound C3bi by C3b inactivator, Molec. Immunol., 19, 1386 (Abstract) (1982).

65. Gaither T. A., Hammer . H., Gadek J. E., Katusha K., Frank M. M. Cleavage of membrane bound C3b and C3bi by viable human neutrophils, Fed. Proc, 40, 1018 (Abstract) (1981).

66. Medicus R. G., Arnaut M. A . Surface restricted control of C3b INA dependent C3c release from bound C3bi molecules, Fed. Proc, 41, 848 (1981).

67. Weiler J. M.. Doha M. R.. Austen K. F., Fearon D. T. Control of the amplification con-vertase of complement by the plasma protein piH. Proc. Natl. Acad. Sci. USA, 73, 3268 3272 (1976).

68. Lachmann P. J., Muller-Eberhard H. J. The demonstration in serum of "conglutinin acti-

24. vating factor and its effect on the third component of complement, J. Immunol., 100, 691 698 (1968).

69. Medicus R. G., Gotze 0., Muller-Eberhard II. J. Alternative pathway of complement: Recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway, J. Exp. Med., 144, 10761093 (1976).

70. Alper C. A., Abramson N., Johnston R. ., Jandl J. H., Rosen E. S. Increased susceptibility bo infection mediated functions and of the third component of complement (C3), N. Engl. J. Med., 282, 349354 (1970).

71. Thompson R. A., Wlnterborn M. H. Hypocomplementemia due to a genetic deficiency of PIH globulin, Clin. Exp. Immunol., 46, 110 (1981).

72. Pangburn M. K., Muller-Eberhard H. J. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement, J. Exp. Med., 152, 11021114 (1980).

73. Berger M., Gaither T. A., Hammer . H., Frank M. M. Lack of binding of human C3 in its native state to receptors, J. Immunol., 127, 13291334 (1981).

74. Fearon D. T. Regulation by membrane scialic acid of {-dependent decay-dissolution of amplification C3 convertase of the alternative complement pathway, Proc. Natl. Acad. Sci. USA, 75, 1971-1975 (1978).

75. Kazatchkine M. D., Fearon D. ., Austen K. F. Human alternative complement pathway: Membrane-associated scialic acid regulates the competition between p and piH for cell bound , J. Immunol., 122, 7581 (1979).

76. Kazatchkine M. D., Fearon D. ., Silbert J. E., Austen K. F. Surface associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle bound C3b, J. Exp. Med., 150, 12021215 (1979).

77. Fearon D. T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane, Proc. Natl. Acad. Sci. USA, 76, 5867-5871 (1979).

78. Fearon D. T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leucocyte lymphocyte and monocyte, J. Exp. Med., 152, 2030 (1980).

79. Medof M. E., Prince G. M., Mold C. Release of soluble immune adherence receptors is mediated by C3b inactivator independently of B1H and is accompanied by generation , Proc. Natl. Acad. Sci. USA, 79, 50475051 (1982).

80. Moore F. D., Austen K. F., Fearon D. T. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronese, J. Immunol., 128, 13021306 (1982).

81. Nicholson-Weller A., Daha M. R., Austen K. F. Different functions for specific guinea pig IgG, and IgG2 in the lysis of sheep erythrocytes by C4-deficient guinea pig serum, J. Immunol., 126, 18001804 (1981).

82. Schenkein H. A., Ruddy S. The role of immunoglobulins in alternative pathway activation by zymosan, J. Immunol., 126, 710 (1981).

83. Frank M. M., Gaither T. A., Adkinson F., Terry W. D., May J. E. Activation of the alternate complement pathway by human immunoglobulins, J. Immunol., 116, 1733 (Abstract) (1976).

84. Edwards M. S., Kasper D. L., Jennings H. J., Baker C. J., Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group streptococci, J. Immunol., 128, 12781283 (1982).

85. Moore F. D., Fearon D. ., Austen K. F. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b, J. Immunol., 126, 18051809 (1981).

86. Winkelstein J. A., Shin H. S. The role of the Immunoglobulin in the interaction of pneu-mococci and the properdin pathway: Evidence for its specificity and lack of requirement for the Fc portion of the molecule, J. Immunol., 112, 16351641 (1974).

87. Nelson ., Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement, J. Immunol., 122, 19941999 (1979).

88. Ballow M., Cochrane C. G. Two anticomplementary factors in cobra venom: Hemolysis of guinea pig erythrocytes by one of them, J. Immunol., 103, 944952 (1969).

89. Jo

35
< > 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121

". 3" (4.83Mb)


[]  []  [ ]  [ ]


Rambler's Top100

Copyright 2009
(25.04.2017)